Insider Selling: Loxo Oncology Inc (LOXO) CEO Sells 20,000 Shares of Stock
Loxo Oncology Inc (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 20,000 shares of Loxo Oncology stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $166.20, for a total transaction of $3,324,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
LOXO stock traded down $1.38 during mid-day trading on Friday, hitting $164.00. 289,685 shares of the company were exchanged, compared to its average volume of 224,740. The firm has a market cap of $5.02 billion, a P/E ratio of -30.89 and a beta of 2.25. Loxo Oncology Inc has a twelve month low of $71.45 and a twelve month high of $208.95.
Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.15. The company had revenue of $42.60 million for the quarter, compared to analyst estimates of $32.36 million. During the same period in the prior year, the business earned ($0.94) earnings per share. equities research analysts predict that Loxo Oncology Inc will post -0.47 earnings per share for the current fiscal year.
Several research firms recently issued reports on LOXO. BidaskClub downgraded shares of Loxo Oncology from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 28th. Ifs Securities downgraded shares of Loxo Oncology from a “strong-buy” rating to a “market perform” rating in a research note on Monday, June 4th. Citigroup lifted their price target on shares of Loxo Oncology to $178.00 and gave the stock a “buy” rating in a research note on Friday, May 18th. Cann reaffirmed an “average” rating and set a $202.00 price target (up previously from $122.00) on shares of Loxo Oncology in a research note on Thursday, July 12th. Finally, Zacks Investment Research raised shares of Loxo Oncology from a “hold” rating to a “buy” rating and set a $189.00 price target on the stock in a research note on Saturday, August 4th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $188.40.
Loxo Oncology Company Profile
Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.
Featured Article: Growth Stocks
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.